Company intelligence / Profile preview

Smith Biomedical Consulting

Ownership: Private
Development stage: Other

Overview

Smith BioMed has established itself as a leader in rapid, disposable onsite tests for drugs of abuse (urine/saliva) and has expanded into point-of-care medical diagnostics. Their products improve early diagnosis, workplace safety, productivity, and public health outcomes. The company maintains close ties with global pharmaceutical research to ensure access to cutting-edge technology.

Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

Not specified; maintains relationships with global pharmaceutical research/manufacturing organizations

Beyond the preview

Go deeper on Smith Biomedical Consulting.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Smith Biomedical Consulting.

Explore the full profile